{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "21732758",
  "DateCompleted": {
    "Year": "2011",
    "Month": "10",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "11",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2217/fon.11.63"
    ],
    "Journal": {
      "ISSN": "1744-8301",
      "JournalIssue": {
        "Volume": "7",
        "Issue": "7",
        "PubDate": {
          "Year": "2011",
          "Month": "Jul"
        }
      },
      "Title": "Future oncology (London, England)",
      "ISOAbbreviation": "Future Oncol"
    },
    "ArticleTitle": "A new frontier in personalized cancer therapy: mapping molecular changes.",
    "Pagination": {
      "StartPage": "873",
      "EndPage": "894",
      "MedlinePgn": "873-94"
    },
    "Abstract": {
      "AbstractText": [
        "Mutations in the genome of a normal cell can affect the function of its many genes and pathways. These alterations could eventually transform the cell from a normal to a malignant state by allowing an uncontrolled proliferation of the cell and formation of a cancer tumor. Each tumor in an individual patient can have hundreds of mutated genes and perturbed pathways. Cancers clinically presenting as the same type or subtype could potentially be very different at the molecular level and thus behave differently in response to therapy. The challenge is to distinguish the key mutations driving the cancer from the background of mutational noise and find ways to effectively target them. The promise is that such a molecular approach to classifying cancer will lead to better diagnostic, prognostic and personalized treatment strategies. This article provides an overview of advances in the molecular characterization of cancers and their applications in therapy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada."
          }
        ],
        "LastName": "Kasaian",
        "ForeName": "Katayoon",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jones",
        "ForeName": "Steven Jm",
        "Initials": "SJ"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Future Oncol",
    "NlmUniqueID": "101256629",
    "ISSNLinking": "1479-6694"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Epigenomics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Expression Profiling"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genomics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pharmacogenetics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Proteomics"
    }
  ]
}